Likes Subject
https://www.valuewalk.com/is-kintara-therapeutics-a-hidden-gem/ KTRA's next re ADVFN_abullman 01/03/23 11:06 AM
1.62 million outstanding unchanged. Show your proof or
Bullish
Bullish
QuantumTravesty 12/16/22 11:21 AM
Wish they would STOP DILUTING this damn stock.
Bearish
Bearish
retiredtech 12/16/22 10:35 AM
1.62 outstanding unchanged. Proof or it didn’t happen.
Bullish
Bullish
QuantumTravesty 12/15/22 11:43 AM
Dilution machine. retiredtech 12/15/22 11:17 AM
Just after the open MM's are trying to retiredtech 12/15/22 9:34 AM
IF this PPS breaks $12.00 today the PPS retiredtech 12/15/22 9:13 AM
What Is Orphan Drug Status? retiredtech 12/15/22 8:47 AM
Dec. 15, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc.
Bullish
Bullish
QuantumTravesty 12/15/22 8:17 AM
Looking more and more like a SCAM traders. retiredtech 12/14/22 12:51 PM
Starting to suspect DILUTION. With no news retiredtech 12/14/22 10:42 AM
Volume has dropped BIG time. Screenshot: https://investorshub.advfn.com/ui retiredtech 12/13/22 10:59 AM
This is the time in the cycle when retiredtech 12/13/22 10:50 AM
I hope they get funding also. If retiredtech 12/13/22 10:49 AM
With such a low float and potential blockbuster imrichbeotch 12/13/22 9:50 AM
If that much. I hope the company imrichbeotch 12/13/22 9:47 AM
There cannot be more than 200K to 250K retiredtech 12/13/22 9:45 AM
MM are pulling their usual scam crap. imrichbeotch 12/13/22 9:10 AM
I am going to sell today on a retiredtech 12/13/22 5:39 AM
I already sold with a double from 7.20. dinogreeves 12/12/22 11:14 PM
What is happening here is TOTALLY CRIMINAL with retiredtech 12/12/22 5:32 PM
Agree HJ72 12/12/22 1:17 PM
Their priority IS NOT the PPS. It
Bullish
Bullish
retiredtech 12/12/22 1:03 PM
Yes they’re priority is not the PPS. HJ72 12/12/22 11:14 AM
I do not "fear" the dip. I retiredtech 12/12/22 11:10 AM
Don’t fear this little dip we’re holding a HJ72 12/12/22 10:36 AM
IF management lets this stock sit with NO
Bullish
Bullish
retiredtech 12/12/22 10:19 AM
Yes, we will get there regardless. I
Bullish
Bullish
dinogreeves 12/12/22 1:44 AM
FINVIZ says Target Price $150.00
Bullish
Bullish
retiredtech 12/12/22 1:43 AM
Undeniably one of the lowest market cap biotech
Bullish
Bullish
dinogreeves 12/11/22 11:24 PM
One news will send this instantly above $20.
Bullish
Bullish
dinogreeves 12/11/22 11:15 PM
KTRA is waiting to erupt and make a dinogreeves 12/11/22 9:23 PM
MM's doing literally everything they can to STOP retiredtech 12/09/22 3:46 PM
I think most traders are expecting funding for
Bullish
Bullish
retiredtech 12/09/22 1:13 PM
The slow accumulation got me wondering what news imrichbeotch 12/09/22 11:25 AM
Hugely bullish on this one. The pattern
Bullish
Bullish
dinogreeves 12/09/22 12:06 AM
Fantastic close.
Bullish
Bullish
dinogreeves 12/08/22 4:27 PM
Yea this mofo moving nicely imrichbeotch 12/08/22 3:45 PM
Moving like gangbusters now. This float is
Bullish
Bullish
retiredtech 12/08/22 2:54 PM
Up 200%!from the low and my $0.22 shares
Bullish
Bullish
QuantumTravesty 12/08/22 11:36 AM
FINVIZ Target Price 150.00
Bullish
Bullish
retiredtech 12/08/22 7:54 AM
Totally agree with your estimates.
Bullish
Bullish
retiredtech 12/08/22 2:47 AM
Anything is possible with that float and especially
Bullish
Bullish
dinogreeves 12/07/22 11:11 PM
When they publish news about acquiring financing for
Bullish
Bullish
retiredtech 12/07/22 8:13 PM
We should be in the teens by Christmas,
Bullish
Bullish
dinogreeves 12/07/22 12:19 PM
Anticipation is moving the market. With an retiredtech 12/07/22 11:40 AM
Moving nicely. Wonder if they have any prospects? imrichbeotch 12/07/22 10:36 AM
Thanks dino for the info. I retiredtech 12/07/22 4:00 AM
Did you know, they have warrant strike prices
Bullish
Bullish
dinogreeves 12/07/22 12:22 AM
Decent webcast this time,, https://wsw.com/webcast/rhk2/ktra/1608222 QuantumTravesty 12/05/22 8:41 PM
Likes Subject

QuantumTravesty
12/16/22 11:21 AM
retiredtech
12/16/22 10:35 AM
retiredtech
12/15/22 11:17 AM
retiredtech
12/15/22 9:34 AM
retiredtech
12/15/22 9:13 AM
retiredtech
12/15/22 8:47 AM
retiredtech
12/14/22 12:51 PM
retiredtech
12/14/22 10:42 AM
retiredtech
12/13/22 10:50 AM
retiredtech
12/13/22 10:49 AM
imrichbeotch
12/13/22 9:50 AM
imrichbeotch
12/13/22 9:47 AM
retiredtech
12/13/22 9:45 AM
imrichbeotch
12/13/22 9:10 AM
retiredtech
12/13/22 5:39 AM
dinogreeves
12/12/22 11:14 PM
HJ72
12/12/22 1:17 PM
retiredtech
12/12/22 1:03 PM
retiredtech
12/12/22 11:10 AM
retiredtech
12/12/22 10:19 AM
dinogreeves
12/12/22 1:44 AM
retiredtech
12/12/22 1:43 AM
dinogreeves
12/11/22 11:24 PM
dinogreeves
12/11/22 11:15 PM
dinogreeves
12/11/22 9:23 PM
retiredtech
12/09/22 1:13 PM
imrichbeotch
12/09/22 11:25 AM
dinogreeves
12/09/22 12:06 AM
dinogreeves
12/08/22 4:27 PM
imrichbeotch
12/08/22 3:45 PM
retiredtech
12/08/22 2:54 PM
QuantumTravesty
12/08/22 11:36 AM
retiredtech
12/08/22 7:54 AM
retiredtech
12/08/22 2:47 AM
dinogreeves
12/07/22 12:19 PM
retiredtech
12/07/22 11:40 AM
imrichbeotch
12/07/22 10:36 AM
retiredtech
12/07/22 4:00 AM
dinogreeves
12/07/22 12:22 AM

Kintara Therapeutics Inc. (KTRA)

Followers
49
Posters
149
Posts (Today)
0
Posts (Total)
1230
Created
01/25/13
Type
Free
Moderators QuantumTravesty

  https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.

           VAL-083 Shows Potential Against Multiple Cancers 

VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.

VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.

We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.

 

REM-001 is a Proprietary Late Stage Photodynamic Therapy (“PDT”) Platform 

REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.

Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.   

11/03/21

Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.

“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.

Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post